Pancreatic cancer remains a formidable challenge for clinicians,with a notoriously low five-year survival rate of just 13% [[3]], and often a late-stage diagnosis. Despite these grim statistics, researchers are making incremental progress in understanding and treating this aggressive disease. This article details promising new research avenues, spearheaded by the Fondation ARC contre le cancer, focusing on early detection, overcoming treatment resistance, and innovative therapeutic approaches currently under examination.
Pancreatic Cancer Survival Rate Remains Low, But New Research Offers Hope
Table of Contents
Pancreatic cancer is often diagnosed at a late stage, after the tumor has spread beyond the pancreas. This delayed detection is due, in part, to the fact that symptoms often don’t appear until the cancer is advanced, and those symptoms can be easily attributed to other, less serious conditions. This often leads to delays in diagnosis and treatment.
Unfortunately, by the time pancreatic cancer is detected, it’s often too late for surgery, which is currently the only potentially curative treatment. In these cases, patients typically undergo aggressive chemotherapy, which isn’t always effective. This underscores the urgent need for new diagnostic tools and therapies, according to the Fondation ARC contre le cancer.
Promising New Therapeutic Approaches Under Investigation
With the incidence of pancreatic cancer on the rise and a lack of specific early warning signs, projections indicate that it could become the second leading cause of cancer death in Europe and the United States by 2030 if new treatment strategies aren’t developed. In response, the Fondation ARC launched the PANCREAS project call in 2022 to support innovative research.
The goal of the PANCREAS project is to “support innovative work around early diagnosis, new therapeutic approaches for patients who are not eligible for surgery, and actionable targets in the tumor microenvironment, in order to overcome the resistance of these cancers.” Early detection and more effective treatments are crucial for improving outcomes for patients facing this challenging diagnosis.
Foundation Highlights Three Key Research Projects
Overcoming Resistance to Chemotherapy and Immunotherapy: Researchers at the Centre Georges François Leclerc in Dijon, led by Pr François Ghiringhelli, are investigating the role of interleukin-1 (IL-1), a protein produced by the immune system. Their hypothesis is that IL-1 allows tumor cells to protect themselves from treatment. The team is working to determine if blocking the IL-1 pathway could restore sensitivity to chemotherapy and immunotherapy.
Using Gene Therapy to Enhance Immunotherapy: Pr Sandrine Dabernat of the Institut de Recherche en Oncologie de Bordeaux and her team are developing an innovative gene therapy approach. “We are proposing an innovative gene therapy to create breaches in the tumor microenvironment and attract anti-tumor immune cells, making patients eligible for cellular immunotherapy,” she explained. The therapy involves introducing modified viruses into the body to target pancreatic cancer cells, making them more vulnerable to attack by the immune system.
Early Detection Through Liquid Biopsy: Researchers are exploring the potential of liquid biopsies – simple blood tests – to detect pancreatic cancer at its earliest stages. “This approach analyzes biological specificities of immune cells associated with the detection of precancerous pancreatic lesions or pancreatic cancer at an early stage.” Earlier diagnosis would expand surgical options for more patients.
Recognizing the Early Warning Signs
Vigilance and awareness of potential symptoms are key to early detection. The Centre Anti-Cancer Léon-Bérard in Lyon has compiled a list of signs that should prompt a visit to a doctor:
– Jaundice;
– Abdominal pain;
– Mid-back pain;
– Recent-onset diabetes;
– Thrombosis (blood clot);
– Changes in bowel habits;
– Unexplained weight loss;
– Nausea;
– Depressive symptoms.
